Anti-Aging Drug Research Mapped Across 20 Years Using Bibliometric Analysis
A sweeping review organizes 20 years of anti-aging pharmacology into three intervention axes and ranks the top compounds by research impact.
Summary
Researchers from Xinjiang Medical University used bibliometric methods to systematically map anti-aging drug research published between 2005 and 2025. Rather than ranking drugs by clinical success, they prioritized compounds by their prominence in the scientific literature and analyzed how well each translates to human use. The review identifies three overlapping therapeutic axes: senolytics and senomorphics targeting cellular senescence, nutrient-sensing modulators affecting mTOR, AMPK, and autophagy, and homeostasis-restoring agents that support redox balance, inflammation control, and circadian rhythm. A top-ten list of anchor compounds emerged from this analysis. The authors argue that the field has matured from simple lifespan-extension experiments into a more precise, hallmark-guided framework aimed at targeting the root biological drivers of aging across multiple pathways simultaneously.
Detailed Summary
Anti-aging pharmacology has grown from isolated lifespan experiments into a sophisticated, multi-target discipline. This review matters because the sheer volume of aging research makes it difficult for clinicians and researchers to identify which compounds have the strongest evidence base and realistic translational potential. A structured, data-driven map of the field is increasingly necessary.
The authors employed a bibliometric-guided, strategy-oriented approach to survey the explicit anti-aging drug literature from 2005 to 2025. Bibliometrics uses quantitative analysis of publications, citations, and co-authorship networks to identify influential work. This methodology allowed the team to prioritize compounds based on scientific prominence rather than clinical ranking alone, offering a complementary perspective to traditional systematic reviews.
The analysis converged on three partially overlapping intervention axes. The first encompasses senotherapeutics, including senolytics and senomorphics, which target cellular senescence and senescence-associated secretory phenotype signaling. The second covers nutrient-sensing and metabolic gerotherapeutics that modulate mTOR, AMPK, autophagy, and mitochondrial adaptation. The third axis involves homeostasis-restoring agents that reinforce redox balance, inflammatory regulation, and circadian resilience. A top-ten list of anchor compounds was identified, though specific drugs were not named in the abstract.
The implications are significant for both researchers and clinicians. The hallmark-informed framework clarifies that compounds engaging multiple aging hallmarks simultaneously may offer superior functional outcomes compared to single-target interventions. Emerging candidates and platform innovations are noted as promising areas for precision geromedicine.
Key caveats apply. This summary is based on the abstract only, so granular compound-level data and the full top-ten list are unavailable for review. Bibliometric prominence does not equal clinical efficacy, and many highly cited compounds remain far from approved human therapies. The institutional base is a single Chinese university, which may introduce geographic publication bias.
Key Findings
- Anti-aging pharmacology now organizes around three axes: senolytics, nutrient-sensing modulators, and homeostasis-restoring agents.
- A bibliometric top-ten list of anchor compounds was identified from 20 years of anti-aging drug literature.
- Multi-hallmark engagement by a single compound appears linked to better functional aging outcomes.
- Many high-citation compounds still face significant barriers to human clinical translation.
- Emerging candidates and platform technologies signal ongoing progress toward precision geromedicine.
Methodology
The review applied bibliometric analysis to the anti-aging drug literature published between 2005 and 2025, using citation networks and publication data to identify influential compounds and research trends. This approach was combined with a strategy-oriented narrative synthesis integrating mechanistic, preclinical, and translational evidence. Compound prioritization was based on bibliometric prominence rather than clinical trial outcomes.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access; specific compound names, data tables, and detailed findings are unavailable. Bibliometric rankings reflect publication activity, not clinical efficacy or safety. The study originates from a single institution in China, which may introduce regional publication bias in the literature sampled.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: